StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
PTGXProtagonist Therapeutics, Inc
stockpulse.co.kr
Nasdaq
$141.04▲ 1.92%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.07BShares out 64.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

21
  • 10.2After-hours26.10.03 05:10
    4Ownership#●●●

    Protagonist Therapeutics, Inc

    Executive Ali Asif of Protagonist Therapeutics reported a change in beneficial ownership of securities as of September 30, 2026. This filing serves as a formal disclosure of insider equity transactions via Form 4.…more

    $141.04+1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.30After-hours26.10.01 05:20
    144Ownership

    Protagonist Therapeutics, Inc

    Protagonist Therapeutics insider Ali Asif has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard regulatory filing disclosing the insider's plan to dispose of their holdings.…more

    $141.04+1.92%vs prev close
    View filingShare
  • 9.11Overnight26.09.11 10:17
    4Ownership

    Protagonist Therapeutics, Inc

    Dr. Dinesh V. Patel, an insider at Protagonist Therapeutics, reported a change in his beneficial ownership of company securities as of September 8, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's stock holdings.…more

    $141.04+1.92%vs prev close
    View filingShare

20 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.8After-hours26.09.09 05:07
    Bullish#●●●#●●●

    Protagonist Therapeutics Announces $300M Share Repurchase Program

    Protagonist Therapeutics has authorized a share repurchase program to buy back up to $300 million of its outstanding common stock. This initiative reflects the company's commitment to returning value to shareholders.…more

    $141.04+1.92%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.31Regular26.09.01 01:38

    ●●●●●●●● ●●●●● ●●●●●●

    Takeda Pharmaceutical has received FDA approval for MIMRYLO, a treatment for polycythemia vera, following successful Phase 3 clinical trials. This regulatory milestone strengthens the company's drug portfolio and is expected to contribute to future revenue growth.…more

    $141.04+1.92%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →